抗血小板药和抗凝药的临床合理应用创新.ppt

* As a result of these analyses, the authors were able to add to current knowledge of antiplatelet therapy. They were able to conclude that where patients have a contraindication to ASA, the ADP-receptor antagonist clopidogrel is an appropriate alternative, and that in certain clinical circumstances, the addition of a second antiplatelet drug to ASA may produce additional benefits. They do, however, note that more research into this strategy is needed.1,2 It is important to note that the CURE trial publication was outside the time window of this meta-analysis, and we now know that clopidogrel